Cargando…
Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation independently of the effects on cholesterol metabolism. The current analysis showed that our 156 patie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385877/ https://www.ncbi.nlm.nih.gov/pubmed/37515197 http://dx.doi.org/10.3390/v15071511 |
_version_ | 1785081520827924480 |
---|---|
author | Mester, Patricia Amend, Pablo Schmid, Stephan Müller, Martina Buechler, Christa Pavel, Vlad |
author_facet | Mester, Patricia Amend, Pablo Schmid, Stephan Müller, Martina Buechler, Christa Pavel, Vlad |
author_sort | Mester, Patricia |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation independently of the effects on cholesterol metabolism. The current analysis showed that our 156 patients with systemic inflammatory response syndrome (SIRS) or sepsis had higher plasma PCSK9 levels in contrast with the 68 healthy controls. COVID-19 sepsis patients had increased plasma PCSK9 levels in comparison to sepsis patients not infected by SARS-CoV-2. For further analysis, patients were divided in two groups based on COVID-19. In both sub-cohorts, plasma PCSK9 levels did not correlate with C-reactive protein, leukocyte count, and procalcitonin. Plasma PCSK9 levels of both patient groups did not significantly differ among SIRS/sepsis patients with and without dialysis and patients with and without ventilation. Furthermore, vasopressor therapy was not significantly associated with altered plasma PCSK9 levels. In the non-COVID-19 SIRS/sepsis group, patients with Gram-negative and Gram-positive infections had similar plasma PCSK9 levels as patients without a detectable pathogen in their blood. In conclusion, the current study suggests PCSK9 as a possible biomarker for COVID-19, but this needs to be validated in larger cohorts. |
format | Online Article Text |
id | pubmed-10385877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103858772023-07-30 Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 Mester, Patricia Amend, Pablo Schmid, Stephan Müller, Martina Buechler, Christa Pavel, Vlad Viruses Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation independently of the effects on cholesterol metabolism. The current analysis showed that our 156 patients with systemic inflammatory response syndrome (SIRS) or sepsis had higher plasma PCSK9 levels in contrast with the 68 healthy controls. COVID-19 sepsis patients had increased plasma PCSK9 levels in comparison to sepsis patients not infected by SARS-CoV-2. For further analysis, patients were divided in two groups based on COVID-19. In both sub-cohorts, plasma PCSK9 levels did not correlate with C-reactive protein, leukocyte count, and procalcitonin. Plasma PCSK9 levels of both patient groups did not significantly differ among SIRS/sepsis patients with and without dialysis and patients with and without ventilation. Furthermore, vasopressor therapy was not significantly associated with altered plasma PCSK9 levels. In the non-COVID-19 SIRS/sepsis group, patients with Gram-negative and Gram-positive infections had similar plasma PCSK9 levels as patients without a detectable pathogen in their blood. In conclusion, the current study suggests PCSK9 as a possible biomarker for COVID-19, but this needs to be validated in larger cohorts. MDPI 2023-07-06 /pmc/articles/PMC10385877/ /pubmed/37515197 http://dx.doi.org/10.3390/v15071511 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mester, Patricia Amend, Pablo Schmid, Stephan Müller, Martina Buechler, Christa Pavel, Vlad Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title | Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title_full | Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title_fullStr | Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title_full_unstemmed | Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title_short | Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19 |
title_sort | plasma proprotein convertase subtilisin/kexin type 9 (pcsk9) as a possible biomarker for severe covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385877/ https://www.ncbi.nlm.nih.gov/pubmed/37515197 http://dx.doi.org/10.3390/v15071511 |
work_keys_str_mv | AT mesterpatricia plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 AT amendpablo plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 AT schmidstephan plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 AT mullermartina plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 AT buechlerchrista plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 AT pavelvlad plasmaproproteinconvertasesubtilisinkexintype9pcsk9asapossiblebiomarkerforseverecovid19 |